IC
VIR icon

Iconiq Capital’s Vir Biotechnology VIR Stock Holding History

Iconiq Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,222,222
Closed -$59.5M – 73
2020
Q4 		$59.5M Hold
2,222,222
– – 1.48% 7
2020
Q3 		$76.3M Sell
2,222,222
-24,672
-1% -$1.06M 4.44% 8
2020
Q2 		$92.1M Sell
2,246,894
-1,086,439
-33% -$36.5M 6.5% 6
2020
Q1 		$114M Sell
3,333,333
-250,000
-7% -$6.72M 10.33% 2
2019
Q4 		$45M Buy
+3,583,333
New +$48M 3.36% 10

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Iconiq Capital's VIR Position: Q1 2021 in Review

Iconiq Capital sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 2,222,222 shares — an estimated $59.5M sold.

Iconiq Capital first reported a position in VIR in Q4 2019 and held it in 5 quarters. The position peaked at $114M in Q1 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Iconiq Capital reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Iconiq Capital sold 2,222,222 Vir Biotechnology shares in Q1 2021, an estimated $59.5M.
  • Iconiq Capital first reported a position in Vir Biotechnology in Q4 2019 and held it in 5 quarters.
  • Iconiq Capital's Vir Biotechnology position peaked at $114M in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Iconiq Capital's 13F filing for Q1 2021, filed 14 May 2021.